CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Allena Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Allena Pharmaceuticals Inc
142 -F North Road, Suite 150
Phone: (617) 467-4577p:617 467-4577 SUDBURY, MA  01776  United States Fax: (617) 916-1871f:617 916-1871

This company's Plan of Liquidation went into effect on 6/20/2023
This company is no longer actively traded on any major stock exchange.

Business Summary
Allena Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Company is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company’s lead product candidate, ALLN-346, is an orally administered, urate-degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The Company is conducting two Phase IIa for ALLN-346. The Company’s wholly owned subsidiaries include Allena Pharmaceuticals Security Corporation (Security Corporation) and Allena Pharmaceuticals Ireland Limited.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202212/31/2021YesYesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Co-Founder Alexey L.Margolin 68 2/1/2019 9/1/2011
Acting Chief Operating Officer, Senior Vice President - Corporate Development GeoffreySwire 49 11/10/2020 11/10/2020
Chief Medical Officer DavidClark 58 12/1/2020 12/1/2020
Independent Director Mark J.Fitzpatrick 4/6/2021 4/6/2021
Independent Director Ann C.Miller 65 10/5/2020 10/5/2020

Business Names
Business Name
Allena Pharmaceuticals
Allena Pharmaceuticals Security Corp.
ALNA
ALNAQ

General Information
Outstanding Shares: 122,083,226 (As of 8/12/2022)
Shareholders: 16
Stock Exchange: OTC
Federal Tax Id: 452729920
Fax Number: (617) 916-1871
Email Address: info@allenapharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 19, 2024